19 results
8-K
EX-99.1
8m2vg
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am
DEF 14A
nkgj9v
22 Apr 21
Definitive proxy
12:35pm
10-K
jxe7mfnh
25 Mar 21
Annual report
12:00am
424B4
eqf3wrm iay6t
10 Jul 20
Prospectus supplement with pricing info
9:35pm
S-1/A
j3eqc8eo6byx15awcw2
2 Jul 20
IPO registration (amended)
5:17pm
S-1/A
EX-10.4
3w2c jcgkqw2s84gimc
2 Jul 20
IPO registration (amended)
5:17pm
S-1
EX-10.2
k3ri4mqwir97f7
19 Jun 20
IPO registration
3:24pm
S-1
5kvzl0fc43 v2vgn
19 Jun 20
IPO registration
3:24pm
DRS/A
6zc16ae3 np
19 May 20
Draft registration statement (amended)
12:00am
DRS/A
eg939cslcar0ki61z
20 Apr 20
Draft registration statement (amended)
12:00am
DRS
r4dp0s1im
28 Feb 20
Draft registration statement
12:00am
- Prev
- 1
- Next